Fig 1: Investigation of roles for SYK and GCK in HCMV infected cells.(A and B) Analysis of siRNA treated cells infected with AD169. HFF were treated with the siRNAs indicated in each figure for 72 hours and infected with 1x105 plaque forming units (p.f.u.) of HCMV. At 96 h.p.i cell lysates were prepared for western blotting (Fig 2A) and viral supernatants were harvested for virus titration (Fig 2B). In Fig 2B viral titre is expressed as plaque forming units/ml (p.f.u./ml) and the mean and standard deviation of 3 experiments is shown. (C) Analysis of HCMV infected cells treated with inhibitors of GCK. HFF cells were infected with AD169 at an MOI of 1 then treated with 1µM of the drug indicated in the figure or the equivalent volume of DMSO. Viral supernatants were harvested at the indicated time points and viral titre (p.f.u./ml) at each time point was determined. (D and E) Western blotting of lysate from uninfected or infected cell lines. Unless stated otherwise, all lysates are from HFF cells. Where indicated, HFF cells were either uninfected or infected with AD169 at an MOI of 1 then treated with either 1µM BAY61-3606, 1µM Maribavir or the equivalent volume of DMSO. Cell lysates were prepared for western blotting at 72 hours post infection. In each panel showing western blotting proteins recognized by the antibodies used in each experiment are indicated to the right of each figure and the positions of molecular weight markers (kDa) are indicated to the left of each figure.
Supplier Page from Abcam for Anti-Germinal Center Kinase/GCK antibody [EPR14304]